The obesity-drug race has been an injectable race. Semaglutide, tirzepatide, retatrutide — all weekly shots. Bioglutide, development code NA-931, is pitching a different shape: an oral small molecule, taken once daily, that is reported to work independently of food. At the 2025 ADA, ENDO, and EASD meetings, Phase 2 data was presented showing 13.8% mean weight loss — and, unusually for this class, no muscle loss.
Bioglutide is described as a quadruple agonist, engineered to activate four pathways at once: IGF-1, GLP-1, GIP, and glucagon. Three of those are the familiar incretin-and-glucagon axis that retatrutide already hits. The fourth — IGF-1 — is the differentiator, and it is the mechanism the readout credits for the muscle-preservation finding. Here is what the Phase 2 data reported, how heavily to weigh it, and where the compound sits against the injectable triple agonists already in research-vendor catalogs.
Research-context information only. Bioglutide (NA-931) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What the Phase 2 Trial Reported
The Phase 2 study is registered on ClinicalTrials.gov as NCT06564753 and was summarized in ADA 2025 late-breaking abstract 2189-LB (published in the journal Diabetes). It was a 13-week, randomized, double-blind, placebo-controlled trial in 125 adults with obesity — enrollment criteria reported as a BMI of at least 30, or at least 27 with a weight-related comorbidity.
The headline efficacy figures, all as reported in the trial:
- 13.8% mean weight loss at the 150 mg/day dose over 13 weeks
- 12.4% placebo-adjusted weight loss
- 72% of participants reached at least 12% weight loss, versus 2% on placebo
On tolerability, the trial reported that gastrointestinal adverse events were mostly mild — nausea and vomiting at 7.3% and diarrhea at 6.3% — the profile that tracks with the GLP-1 component of the molecule. The same dataset was presented at ENDO 2025 and EASD 2025, and a second ADA 2025 abstract (143-OR, also in Diabetes) covered the program.
One caveat frames all of these numbers: they are conference-presented data, not a peer-reviewed journal outcomes paper. Every figure above should be read as single-source until independent publication confirms it. That is the appropriate level of caution for any single-source, conference-stage readout.
The No-Muscle-Loss Finding
The result the readout has emphasized most is what the trial didn't show: muscle loss. Rapid weight loss on incretin agonists carries a well-documented lean-mass cost, and a meaningful fraction of the weight lost on GLP-1-class drugs is muscle. The Phase 2 trial reported no muscle loss, attributed to the IGF-1 agonism built into the molecule — the fourth pathway that separates bioglutide from a pure incretin agonist.
IGF-1 signaling is anabolic for skeletal muscle, so the mechanistic story is coherent: stack an appetite-and-metabolic weight-loss driver (GLP-1/GIP/glucagon) with a muscle-sparing signal (IGF-1) in one molecule. Whether that translates the way the readout describes will need body-composition data — DEXA lean-mass measurements across arms — in a larger trial and a peer-reviewed write-up. As presented, the muscle-preservation claim is conference-reported and not yet independently confirmed.
An earlier Phase 1 study, published in Endocrine Practice, reported roughly 10-13% weight loss over 12 weeks. The Phase 2 readout is framed as confirming and extending that Phase 1 signal at a longer duration and larger sample.
How It Compares to Injectable Triple Agonists
The obvious benchmark is retatrutide, the triple agonist (GLP-1, GIP, glucagon) that reported roughly 24-28% weight loss in its trials. On raw weight-loss percentage, bioglutide's reported 13.8% sits well below that — retatrutide's trial-reported results remain the higher figure in the investigational obesity field.
But the two are not competing on the same axis. Bioglutide is oral, once-daily, and food-independent; retatrutide is a weekly subcutaneous injection. Bioglutide adds an IGF-1 muscle-preservation mechanism that retatrutide does not have. The trials were not head-to-head, run different durations, and enrolled different populations, so a direct percentage-to-percentage ranking overstates what can be concluded. The honest read: retatrutide reported deeper weight loss; bioglutide reported an oral route and a muscle-sparing mechanism. Different trade-offs on the same problem.
Retatrutide is the closest research-available compound sharing three of bioglutide's four target pathways — GLP-1, GIP, and glucagon. The overlap is mechanistic, not a substitution: the two trials are unrelated and were never run head-to-head.
